Convergence Pharmaceuticals Limited

Glaxosmithkline LLC

Neville Hubert Nicholson

Paul John Beswick

Andrew Peter Cridland

Jag Paul Heer

Robert James Gleave

Sadie Vile

Alister Campbell

Lee William Page

Ivan Leo Pinto

Shahzad Sharooq Rahman

The present invention relates to novel piperazine derivatives; to processes for their preparation; to pharmaceutical compositions containing the derivatives; and to the use of the derivatives in therapy to treat diseases for which blocking the Ca2.2 calcium channels is beneficial.

3-pyridylcarbonyl-piperazinylsulfonyl derivatives

The present invention relates to novel piperazine derivatives (I); to processes for their preparation; to pharmaceutical compositions containing the derivatives; and to the use of the derivatives in therapy to treat diseases for which blocking the Ca2.2 calcium channels is beneficial.

Piperazine derivatives used as CAV2.2 calcium channel modulators

The present invention relates to therapeutically active xanthine derivative compounds of Formula (I): corresponding processes for manufacture of said derivatives, pharmaceutical formulations containing and uses of such compounds in therapy, particularly in treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial.

HM74 receptor agonists:xanthine derivatives, corresponding pharmaceutical compositions, treatment methods and processes

Compounds

Growing community of inventors

Harlow, United Kingdom

Neville Hubert Nicholson